Trials / Completed
CompletedNCT02186119
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abicipar pegol | Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol. |
| DRUG | ranibizumab | Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24. |
| OTHER | sham procedure | Sham procedure to the study eye at the visits noted per protocol. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-07-10
- Last updated
- 2015-07-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02186119. Inclusion in this directory is not an endorsement.